Biomotion Sciences Ordinary Shares
Price & Volume
Stats
See more52W Range | $1.42-$26.70 |
Market Cap | $5.3M |
Shares Short | 55,759 |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | $349.09 |
News
See moreYahoo Finance • 3 months ago
Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer
Yahoo Finance • 3 months ago
Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer
Yahoo Finance • 4 months ago
Silexion Therapeutics GAAP EPS of -$2.88
Yahoo Finance • 4 months ago
Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
About
CEO | Mr. Ilan Hadar M.B.A. |
CFO | Ms. Mirit Horenshtein Hadar |
Address | The Goldyne Savad Inst. of Gene Therapy, Jerusalem, Israel, 9112001 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 11 |
